Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Other (Income) Expense Breakdown by Quarter
Other (Income) Expense Breakdown — Foreign Exchange Losses ($M) ($M)
Merck Other (Income) Expense Breakdown: $37M in Q2 2026, down 52.6% from a year earlier.
Latest, Q2 2026
37
Period ended Jun 30, 2026
Change on a year earlier
-52.6%
78 in Q2 2025
History
27 quarters
Since Q2 2017
Sources
19
Documents cited below
Where the Q2 2026 figure comes from
“|| Exchange losses | 37 | 78 | 75 | 167”
Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Reported in Form 8-K Table 4 / Form 10-Q / 10-K Other (Income) Expense Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Merck Other (Income) Expense Breakdown ($M), quarterly Q2 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/other-inc-exp-fx
See every metric in the Merck KPI table. Data updated Oct 26, 2026.